Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Cancer Immunol Res. 2014 Jul 30;2(11):1080–1089. doi: 10.1158/2326-6066.CIR-14-0095

Figure 1.

Figure 1

The inhibition of PI3K and Akt in human T cells selectively inhibits the proliferation of human Treg compared to Tconv in a dose-dependent manner.

Treg (CD4+CD25HI) and Tconv (CD4+CD25−) were fractionated from human PBMCs by cell sorting. Proliferation was examined by dilution of CFSE after stimulation with anti-CD3/anti-CD28 for three days with titrated amounts of TCN, MK-2206, WM and IC87114. Dead cells were excluded by 7AAD incorporation. The left panel represents the average of three experiments, normalized to untreated controls; the right panel shows representative examples.
  1. A significant reduction in Treg proliferation was observed in response to Akt inhibition by TCN compared to that of Tconv at all doses tested: 5uM (p=0.04), 10uM (p=0.03), and 50uM (p=0.01).
  2. A significant reduction of Treg proliferation in response to MK-2206 treatment was observed compared to that of Tconv at the 1uM (p=0.05) and 5uM (p=0.005) doses.
  3. Proliferation of Treg was significantly reduced by WM compared to that of Tconv at all doses tested: 300nM (p=0.03), 800nM (p=0.01) and 1000nM (p=0.002).
  4. Treg proliferation was significantly reduced by IC87114 compared to that of Tconv at the 10uM (p=0.04) and 20uM (p<0.005) doses.